Table 3.
Overall shift in HbA1c from baseline to last available value up to 24-month data cut-off in the 162 patients who received at least one dose of pasireotide
| Baseline | Last reported HbA1c value | |||||
|---|---|---|---|---|---|---|
| <5.7 % | 5.7 to <6.5 % | 6.5 to <8 % | ≥8 % | Missing | ||
| n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | |
| <5.7 % | 80 (49.4) | 14 (8.6) | 32 (19.8) | 27 (16.7) | 2 (1.2) | 5 (3.1) |
| 5.7 to <6.5 % | 48 (29.6) | 2 (1.2) | 7 (4.3) | 26 (16.0) | 12 (7.4) | 1 (0.6) |
| 6.5 to <8 % | 24 (14.8) | 0 | 0 | 5 (3.1) | 18 (11.1) | 1 (0.6) |
| ≥8 % | 2 (1.2) | 0 | 0 | 0 | 2 (1.2) | 0 |
| Missing | 8 (4.9) | 0 | 3 (1.9) | 4 (2.5) | 0 | 1 (0.6) |
| Total | 162 (100.0) | 16 (9.9) | 42 (25.9) | 62 (38.3) | 34 (21.0) | 8 (4.9) |
Italicized values represent the patients with a shift in HbA1c level that indicates a worse diabetic status at the last reported value compared with core baseline. Two patients with HbA1c ≥8 % at study entry received pasireotide treatment (one patient in each treatment arm) and were classed as protocol deviations